Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Traws Pharma (TRAW) just unveiled an announcement.
Steven M. Fruchtman has stepped down as President and Chief Scientific Officer of Traws Pharma, citing “good reason” and expecting severance pay per his employment terms, especially in light of a change in control. However, the company’s board disagrees with his interpretation and believes no severance is owed. Meanwhile, Victor Moyo remains the Chief Medical Officer for Oncology at Traws Pharma.
For a thorough assessment of TRAW stock, go to TipRanks’ Stock Analysis page.